Freienbach, January 8^th 2026 – EffRx Pharmaceuticals SA, a Swiss commercial-stage pharmaceutical company focused on the development and commercialization of treatments for endocrine, metabolic and musculoskeletal disorders, today announced the signing of an exclusive licensing and distribution agreement with Compai Pharma for the commercialization of Binosto^® in Malaysia. Compai Pharma is a leading medical distribution company with strong reach across South East Asia.

BINOSTO^® (buffered soluble alendronate) is indicated for the treatment of osteoporosis in postmenopausal women and for increasing bone mass in men with osteoporosis. It is marketed in multiple regions, including Europe, the United States and Asia. Clinical studies and regulatory labeling confirm its ability to reduce fracture risk and improve bone mineral density. The formulation is designed as a buffered effervescent tablet to be dissolved in water, which may help minimize upper gastrointestinal irritation compared to conventional tablets. Published observational studies report a favorable gastric tolerability profile, supporting adherence to long-term therapy.^1-3

“We are honored to be the exclusive distributor of BINOSTO^® in Malaysia. Osteoporosis remains underdiagnosed and undertreated in our country, and many patients struggle with adherence because of difficulties with pill forms. By introducing BINOSTO^®, we believe we can help fill this gap, offer more patient-friendly options, and improve outcomes for those in need”, said Mahesh Janarthanan, Director-Marketing, Business Development and Strategic Accounts at Compai Pharma.

“We are proud to partner with Compai Pharma to better serve patients with osteoporosis in Malaysia. “This partnership is a cornerstone of our growth strategy in Southeast Asia. It combines our important treatment, BINOSTO^®, with Compai’s strong commercial and regulatory expertise in the local,” said Victor Papavasileiou, EVP Corporate Development at EffRx Pharmaceuticals.

Under the terms of the agreement, EffRx will grant Compai an exclusive license to commercialize BINOSTO^® in Malaysia and will supply the product to Compai.

Destum Partners, Inc. acted as exclusive advisor to Compai Pharma for the transaction.

About BINOSTO^{® 1-3}

Binosto^® (alendronate 70 mg effervescent tablets) is the first and only buffered solution for the treatment of osteoporosis in postmenopausal women and for increasing bone mass in men with osteoporosis.^1,2 It reduces the risk of hip, vertebral and non-vertebral fractures. Binosto^®, taken once weekly dissolved in plain water, delivers fully solubilized alendronate directly to the stomach, which may help reduce local esophageal and gastric irritation associated with particulate forms of alendronate. Observational studies, such as GastroPASS, report a low incidence of upper-GI adverse events, suggesting improved tolerability and adherence.³

Disclaimer: Please refer to the official Binosto^® prescribing information and approved indications, contraindications, and warnings in your country.

About EffRx Pharmaceuticals:

EffRx Pharmaceuticals is a Swiss commercial-stage pharmaceutical company focused on the late-stage development and commercialization of medications for niche endocrine, metabolic and musculoskeletal disorders. EffRx’s lead commercialized product, Binosto^® for the treatment of osteoporosis, is successfully commercialized by Licensees across European, Asian and Middle Eastern countries. EffRx is controlled by Abiogen Pharma S.p.A., an Italian leading company in the field of osteoarticular and bone metabolism diseases.

About Compai Pharma

Compai Pharma is a medical distributor focused on providing high quality treatments to patients across Southeast Asia. With a track record of introducing novel therapies into Malaysia, Compai Pharma specializes in ensuring safe, effective, and timely access to medicines while partnering with global manufacturers to serve unmet medical needs and address women’s health concerns in the region.

References:

1. Europe (SmPC): Binosto 70 mg effervescent tablets – Summary of Product Characteristics. Indicated for treatment of postmenopausal osteoporosis; reduces risk of vertebral and hip fractures. HPRA SmPC PDF 2021 [assets.hpra.ie]
2. United States (FDA Label): BINOSTO prescribing information – indicated for treatment of osteoporosis in postmenopausal women and to increase bone mass in men with osteoporosis. FDA Label 10/2020 [accessdata.fda.gov]
3. Gastric tolerability evidence: GastroPASS study – incidence of upper GI adverse events was low (9.6%, mostly mild), suggesting improved tolerability and adherence. Minisola et al, JBMR Plus 2021; 5(7):e10510.

Contacts:

Compai Pharma

maheshj@compaipharma.com

EffRx Pharmaceuticals

info@effrx.com 

Disclaimer: This communication is intended for institutional purposes and does not constitute promotional or medical communication to the general public.